ATLANTA, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that data from nine ILUVIEN® studies have been accepted for presentation during the 2017 Annual Meeting of the American Academy of Ophthalmology (AAO) at the Ernest N. Morial Convention Center in New Orleans, November 11 -14. In addition, Alimera is sponsoring two special educational events at the meeting.
"We are delighted that nine ILUVIEN data sets have been accepted for presentation at the Academy this year," said Dan Myers, CEO of Alimera. "Eight of the presentations focus on ILUVIEN for diabetic macular edema and include further analyses of our FAME data, as well as updated data from our two U.S. real-world studies, USER and PALADIN. Safety results from the 12-month study on the FAc insert in noninfectious, posterior segment uveitis will also be presented. This is particularly exciting as we are preparing our submission for ILUVIEN for noninfectious, posterior uveitis to the European authorities."
The presentations are scheduled as follows:
From the podium:
Sunday, Nov. 12:
- 9:18 a.m. - 9:25 a.m. - Dr. Careen Yen Lowder, M.D., Ph.D., "Fluocinolone Acetonide Intravitreal Insert in Noninfectious, Posterior Segment Uveitis: 12-Month Safety Results."
- 10:36 a.m. - 10:43 a.m. - Sam Mansour, M.D., "PALADIN, a Phase 4 Study with ILUVIEN: Initial Safety and Efficacy Outcomes with Intravitreal Fluocinolone Acetonide 0.2 µg/day in Diabetic Macular Edema."
- 11:00 a.m. - 11:07 a.m. - Daniel Kiernan, M.D., "Year 3 Visual Acuity Response in Early Nonresponders to 0.2µg/day Fluocinolone Acetonide Implants: The FAME Study."
Posters:
Sunday, Nov. 12:
- 12:45 p.m. - 1:45 p.m. - Alexander Eaton, M.D., "Real-World IOP and Cataract Surgery Outcomes following 0.19-mg Fluocinolone Acetonide Implant: USER Study."
Monday, Nov. 13:
- 12:45 p.m.- 1:45 p.m. - Nathan Radcliffe, M.D., "Effectiveness of Selective Laser Trabeculoplasty on Elevated IOP after 0.19-mg Fluocinolone Acetonide Implant."
- 12:45 p.m. - 1:45 p.m. - Lauren Mason, B.S., "Fluocinolone Acetonide Intravitreal Implant vs. Combined Vitrectomy with Implant for Chronic Diabetic Macular Edema."
- 12:45 p.m. - 1:45 p.m. - Dilraj Grewal, M.D., "Effect of Fluocinolone Acetonide 0.2 µg/day Implant (ILUVIEN) on the Decision to Drive in Patients with Diabetic Macular Edema."
- 12:45 p.m. - 1:45 p.m. - Michael Singer, M.D., "Area-Under-the-Curve Analysis of Fluocinolone Acetonide 0.2 µg/day Implant vs. Ranibizumab Plus Deferred Laser."
- 12:45 p.m. - 1:45 pm - Caesar Luo, M.D., "Early Anatomic vs. Long-term Vision Changes with 0.2 µg/day Fluocinolone Acetonide Implant in Diabetic Macular Edema."
Alimera Sciences-sponsored educational events during AAO:
Peer-to-Peer "Microdose of Reality Event," Saturday, Nov. 11, 5:30 - 8:30 p.m. at the Westin New Orleans Canal Place. This Alimera-sponsored panel discussion on real-world DME data. Register at http://tinyurl.com/MICRODose-of-Reality.
Lunch symposium, "Continuous DME Therapy: Clinical Evidence Through Real Word Evidence," Sunday, Nov.12, 12 noon - 1:30 p.m. Speakers: Nancy M. Holekamp, M.D., Daniel F. Kiernan, M.D. and Fahd Quhill, M.D. This event is presented by Alimera Sciences in collaboration with EyeNet, the news magazine for Ophthalmologists.
About ILUVIEN
ILUVIEN'S U.S. Indication
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months to treat the disease consistently every day.
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME. As the population of people with diabetes increases, Alimera expects the annual incidence of diagnosed DME to increase, as well.
About Alimera Sciences, Inc.
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
For press inquiries:
Katie Brazel
for Alimera Sciences
404-317-8361
kbrazel@bellsouth.net
For investor inquiries:
CG Capital
for Alimera Sciences
877-889-1972
investorrelations@cg.capital